BJDX
Bluejay Diagnostics, Inc.
Last earnings -3.7% on 2026-05-07
$2.93
▼ -11.48%$2.93▼ -54.78%
over 1Y
L $1.67EODHDH $14.00
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today-11.5%
1W-11.5%
1M+49.9%
3M+49.5%
YTD+11.8%
1Y-54.8%
Sell
Conviction
Horizon
Medium (3–12mo)
Street · 6 analysts
Sell
Conservative balance sheet (liabilities/equity 0.19x); but unprofitable (net margin -2750.0%).
Revenue (FY2022) $249K · FY2022
Bluejay Diagnostics, Inc. shows $249K in FY2022 revenue, a -2750.0% net margin, and -114.6% ROE.
Financials · annual, by fiscal year
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | — | $249K | — | — | — |
| Gross profit | — | $48.9K | — | — | — |
| Operating income | -$3.23M | -$9.32M | -$10.3M | -$7.17M | -$6.95M |
| Net income | -$3.49M | -$9.30M | -$9.95M | -$7.72M | -$6.85M |
| Diluted EPS | -$0.41 | -$9.22 | -$3,631.48 | -$456.75 | -$15.25 |
| Net margin | — | -3733.1% | — | — | — |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Key statistics
Valuation
Enterprise value-$2.32M
EV / EBITDA—
EV / Sales-9.3
EV / FCF—
P / FCF—
PEG (trailing)—
Earnings yield-240.4%
FCF yield-218.6%
Quality & risk
ROIC (est.)-91.9%
Free cash flow-$6.23M
Total debt—
Net cash$5.16M
Altman Z-Score-9.13 distress
Piotroski F-Score2/6
Capital returns
Buyback yield—
Dividend yield (est.)—
Shareholder yield—
Shares Δ YoY+75.5%
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Disclosure timeline
SEC · 8-Ks + reportsSome governance/structural items recently, but no outright red flags.
- S-3 Shelf registration (potential raise)2026-06-17
- 8-K Officer / director change2026-06-09
- 8-K Material agreement2026-06-08
- 8-K Material agreement2026-06-02
- 8-K Earnings results2026-05-07
- 10-Q Quarterly report2026-05-07
- DEF 14A Proxy statement2026-04-30
- 8-K Reg FD disclosure2026-04-07
- 8-K Material agreement2026-03-17
Recent filings
all on EDGAR ↗424B3Filing2026-06-26open ↗S-3Filing2026-06-17open ↗8-KPeriod ending 2026-06-092026-06-09open ↗8-KPeriod ending 2026-06-022026-06-08open ↗SCHEDULE 13GFiling2026-06-05open ↗SCHEDULE 13D/AFiling2026-06-02open ↗SCHEDULE 13D/AFiling2026-06-02open ↗8-KPeriod ending 2026-05-272026-06-02open ↗4Period ending 2026-03-142026-05-18open ↗4Period ending 2026-03-142026-05-18open ↗4Period ending 2026-03-142026-05-18open ↗4Period ending 2026-03-142026-05-18open ↗
Frequently asked
- Is Bluejay Diagnostics, Inc. (BJDX) a buy?
- BJDX currently carries a Sell rating with 3/5 conviction, derived from its latest SEC filings. Conservative balance sheet (liabilities/equity 0.19x); but unprofitable (net margin -2750.0%).
- What is Bluejay Diagnostics, Inc.'s quality score?
- BJDX scores 47.470588235294116/100 (grade D) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.
Sources: SEC EDGAR (CIK 0001704287, latest 10-Q filed 2026-05-07) · EODHD · as of 6/24/2026, 1:17:40 PM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.